Navigation Links
Beanstalk Capital Ltd. enters into arrangement agreement with iCo Therapeutics Inc.
Date:10/16/2007

p>Directors

Sidney Himmel, CA - Chairman and Director

Sidney Himmel, who is currently the president and chief executive officer of Trigon Uranium Corp., has over 17 years experience in Canadian capital markets. Mr. Himmel previously served as vice-president and director for Toronto Dominion Securities, where he specialized in biotechnology, and worked as a corporate finance specialist at Merrill Lynch Canada Ltd. During his time in the investment banking industry, Mr. Himmel participated in the financing of numerous growth and large capitalization companies raising capital in both public and private financial settings. Mr. Himmel was involved with equity institutional sales and trading with Toronto Dominion Securities, where he headed up the preferred share sales desk of Toronto Dominion Securities. Mr. Himmel holds a Bachelor of Sciences and Bachelor of Arts from the University of Toronto. He is a member of both the American Chemical Society and the Institute of Chartered Accountants of Ontario.

Andrew J. Rae, MBA - Director, President and Chief Executive Officer

Andrew Rae has spent a decade in the biotechnology industry, most recently as the chief financial officer of Ability Biomedical Corporation, which was acquired by Medarex, Inc. in 2004. Mr. Rae has also served as vice-president of finance and corporate affairs with Active Pass Pharmaceuticals, Inc. During his tenure at both Active Pass and Ability Biomedical, Mr. Rae raised approximately $20 million in the aggregate in venture financing, engaged in a successful cross-border acquisition transaction and played a significant role in shaping multiple business development deals. Before joining Active Pass, Mr. Rae served as a biotechnology equities analyst for Goepel Shields & Partners (now Raymond James Canada), where he covered Canadian biotechnology stocks including Angiotech Pharmaceuticals, Inc., QLT Inc. and ID Biomedical Corp. Mr. Rae currently sits on the Dean's External Advisor
'/>"/>

SOURCE Beanstalk Capital Ltd.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Gay capital reeling with rising HIV infection
2. Drugs Manufacturers Capitalizing On The Surge In Demand For Bone Health Care
3. Meningitis is rocking the capital again
4. India Crowned As the Diabetic Capital
5. China Crowned the Diabetic Capital of the World
6. Low Awareness Of Kawasaki Disease In Capital: Parents Form Support Group
7. Zagreb, capital of Croatia, affected by first bird flu case
8. Chikungunya in the Capital
9. Dengue Outbreak in the Capital is not an Epidemic: Government
10. Private Health Clinics in the Capital on Strike
11. Migration is the Cause for Fresh Polio Cases in the Capital: Sheila Dikshit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/26/2014)... December 26, 2014 Yisrayl Hawkins, Pastor at ... open letter in light of the Ferguson, Missouri unrest. Yisrayl ... civil unrest and explains why it has only increased. ... was even created. He says there is a very specific ... also says there is a set of rules, or Laws ...
(Date:12/26/2014)... (PRWEB) December 26, 2014 Pentec Health, ... in the state of Pennsylvania for 2014. The awards ... statewide programs of its kind in the country. The ... the Pennsylvania Department of Community and Economic Development, the ... Management and the Central Penn Business Journal. ...
(Date:12/25/2014)... The click strand woven bamboo flooring ... Today, the business announces a click strand woven ... 30, 2015. , Click strand woven bamboo flooring ... a well-known brand in the bamboo industry. It ... reliable bamboo flooring supplier. , “We are happy ...
(Date:12/25/2014)... the popular online supplier of wedding dresses and special occasion ... black one-shoulder cocktail dresses . In addition, all these elegant ... prices, up to 70% off. , The development ... You know, we have thousands of frequent callers in the ... can visit our website for more details. The current special ...
(Date:12/25/2014)... California (PRWEB) December 25, 2014 Helen ... home in Woodland Hills, California after an 8 year ... away on Christmas Eve evening in her home in ... aggressive metastatic breast cancer. , As ... over forty years, she pioneered and championed many of ...
Breaking Medicine News(10 mins):Health News:Yisrayl Hawkins Pleads for Peace in Ferguson and Beyond in New Open Letter 2Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 2Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 3Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:iFitDress.com: Black One-Shoulder Cocktail Dresses for 2015 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 4
... Improving Healthcare , , PLANO, Texas, Dec. 5 Edition 1 ... Vice President and Chief Medical, ... Vice President for Marwood Group, What: "Looking Forward: Perspectives ... hosted by Dr. Harry Greenspun, Executive Vice President and, ...
... another reason to quit smoking, consider that it may diminish ... the University of Rochester Medical Center have found that women ... were significantly more likely to face fertility problems and suffer ... non-smoking women showed those who were exposed to second hand ...
... The board of directors,for Hillenbrand, Inc. (NYSE: ... of $0.185 per share on the company,s common stock, ... $0.1825 per share. The dividend,is payable Dec. 31, 2008, ... Dec. 17, 2008. Hillenbrand has paid quarterly dividends since ...
... at 62nd Annual Meeting of the American Epilepsy Society , ... New studies presented at the 62nd annual meeting of the ... the course of epilepsy diagnosis and management to improve the ... These studies are among the hundreds of developments in the ...
... State Budget Crisis Threaten Seniors, Access to Quality Care, LTC ... Dec. 5 Commenting on the legislative year ahead ... comments today that skilled nursing facilities (SNFs) should not receive ... the nation,s leading long term care advocacy organizations today said ...
... skills , , FRIDAY, Dec. 5 (HealthDay News) -- College students ... might want to get some sleep instead. And not just ... test. , That,s the message from a new study that ... you learn during the day. , Study participants who learned ...
Cached Medicine News:Health News:Looking Forward: Perspectives on Healthcare and Information Technology 2Health News:Looking Forward: Perspectives on Healthcare and Information Technology 3Health News:Secondhand smoke raises odds of fertility problems in women 2Health News:New Research Reports on Interventions that May Alter the Course of Epilepsy Diagnosis and Management 2Health News:New Research Reports on Interventions that May Alter the Course of Epilepsy Diagnosis and Management 3Health News:New Research Reports on Interventions that May Alter the Course of Epilepsy Diagnosis and Management 4Health News:New Research Reports on Interventions that May Alter the Course of Epilepsy Diagnosis and Management 5Health News:Long Term Care Sector Supports and Is Well-Positioned to Advance Health Care Reform, Bolster Economic Stimulus 2Health News:Long Term Care Sector Supports and Is Well-Positioned to Advance Health Care Reform, Bolster Economic Stimulus 3Health News:To Sleep, Perchance to Remember 2Health News:To Sleep, Perchance to Remember 3
(Date:12/24/2014)... Mexico , Dec. 24, 2014  Novastem, ... of its first patient in its study for ... the American Stroke Association, ischemic strokes account for ... to enroll qualified patients in the study, entitled ... Administration of Allogeneic Mesenchymal Stem Cells and Intrathecal ...
(Date:12/24/2014)...  Commonwealth Cornerstone Group (CCG) today announced the completion of ... to help fund the expansion and consolidation of healthcare services ... . PHN is the largest federally ... It is the largest employer in Sharon,s ... staff. Currently, PHN Sharon offers scattered services out ...
(Date:12/24/2014)... , Dec. 24, 2014 Kinex Pharmaceuticals announced ... KX2-361 at Roswell Park Cancer Institute. KX2-361 ... drug that has shown potent inhibitory activity against a ... that are resistant to Temozolomide (T98G), the most widely ... a well-established brain tumor mouse model, KX2-361 consistently clears ...
Breaking Medicine Technology:Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 2Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 3Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 4Commonwealth Cornerstone Group Announces $8 Million in Tax Credits to Expand and Consolidate Healthcare Services in Sharon 2Commonwealth Cornerstone Group Announces $8 Million in Tax Credits to Expand and Consolidate Healthcare Services in Sharon 3Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 2Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 3
... Inovio Pharmaceuticals, Inc. (NYSE AMEX: INO ) today ... Total revenue was $2.6 million and $8.2 million for the ... million and $3.8 million for the same periods in 2010. ... September 30, 2011, were $9.0 million and $24.0 million as compared ...
... UCB today announced new ... (certolizumab pegol) was associated with a rapid and sustained ... of moderate to severe rheumatoid arthritis (RA) patients. The ... 2011 Annual Scientific Meeting in Chicago, November 5-9, are ...
Cached Medicine Technology:Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results 2Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results 3Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results 4Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results 5Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results 6Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results 7Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results 8Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results 9New Data From REALISTIC Study Showed Cimzia® (certolizumab pegol) Provided Rapid and Sustained Efficacy, Over 28 Weeks, in a Broad Population of Patients With Moderate to Severe Rheumatoid Arthritis (RA) Including Those Who Discontinued Prior Anti-T 2New Data From REALISTIC Study Showed Cimzia® (certolizumab pegol) Provided Rapid and Sustained Efficacy, Over 28 Weeks, in a Broad Population of Patients With Moderate to Severe Rheumatoid Arthritis (RA) Including Those Who Discontinued Prior Anti-T 3New Data From REALISTIC Study Showed Cimzia® (certolizumab pegol) Provided Rapid and Sustained Efficacy, Over 28 Weeks, in a Broad Population of Patients With Moderate to Severe Rheumatoid Arthritis (RA) Including Those Who Discontinued Prior Anti-T 4New Data From REALISTIC Study Showed Cimzia® (certolizumab pegol) Provided Rapid and Sustained Efficacy, Over 28 Weeks, in a Broad Population of Patients With Moderate to Severe Rheumatoid Arthritis (RA) Including Those Who Discontinued Prior Anti-T 5New Data From REALISTIC Study Showed Cimzia® (certolizumab pegol) Provided Rapid and Sustained Efficacy, Over 28 Weeks, in a Broad Population of Patients With Moderate to Severe Rheumatoid Arthritis (RA) Including Those Who Discontinued Prior Anti-T 6New Data From REALISTIC Study Showed Cimzia® (certolizumab pegol) Provided Rapid and Sustained Efficacy, Over 28 Weeks, in a Broad Population of Patients With Moderate to Severe Rheumatoid Arthritis (RA) Including Those Who Discontinued Prior Anti-T 7New Data From REALISTIC Study Showed Cimzia® (certolizumab pegol) Provided Rapid and Sustained Efficacy, Over 28 Weeks, in a Broad Population of Patients With Moderate to Severe Rheumatoid Arthritis (RA) Including Those Who Discontinued Prior Anti-T 8New Data From REALISTIC Study Showed Cimzia® (certolizumab pegol) Provided Rapid and Sustained Efficacy, Over 28 Weeks, in a Broad Population of Patients With Moderate to Severe Rheumatoid Arthritis (RA) Including Those Who Discontinued Prior Anti-T 9New Data From REALISTIC Study Showed Cimzia® (certolizumab pegol) Provided Rapid and Sustained Efficacy, Over 28 Weeks, in a Broad Population of Patients With Moderate to Severe Rheumatoid Arthritis (RA) Including Those Who Discontinued Prior Anti-T 10New Data From REALISTIC Study Showed Cimzia® (certolizumab pegol) Provided Rapid and Sustained Efficacy, Over 28 Weeks, in a Broad Population of Patients With Moderate to Severe Rheumatoid Arthritis (RA) Including Those Who Discontinued Prior Anti-T 11
Platelet Aggregation Profiler...
... Eclipse,Plus or 850 ECG medical ... capability. Doctors,maintain all the benefits ... and gain the,ability to view ... personal computers., With diagnostic-quality viewing ...
... The Vision5L Digital ... 5- or 7-lead, ... a signal preview,screen. ... using a compact,flash ...
... provides three contrast levels (high, 9.5 % and ... This test is designed to detect very subtle ... lens evaluation or due to refractive surgery. The ... same contrast and acuity levels as the lower ...
Medicine Products: